Home News Quantitative Analysis of Seven New Prostate Cancer Biomarkers and the Potential Future of the ‘Biomarker Laboratory’

Quantitative Analysis of Seven New Prostate Cancer Biomarkers and the Potential Future of the ‘Biomarker Laboratory’

Two of Aquila’s leading Histologists have recently co-authored and published in MDPI. Mike Millar (Chief Technical Officer) and Mariana Beltran (Senior Scientist) published “Quantitative Analysis of Seven New Prostate Cancer Biomarkers and the Potential Future of the ‘Biomarker Laboratory’”, which highlights a novel Tissue Microarray based approach that could potentially bring cancer biomarkers into clinical usage.

Abstract

Prostate cancer is the third highest cause of male mortality in the developed world, with the burden of the disease increasing dramatically with demographic change. There are significant limitations to the current diagnostic regimens and no established effective screening modality. To this end, research has discovered hundreds of potentials ‘biomarkers’ that may one day be of use in screening, diagnosis or prognostication. However, the barriers to bringing biomarkers to clinical evaluation and eventually into clinical usage have yet to be realised. This is an operational challenge that requires some new thinking and development of paradigms to increase the efficiency of the laboratory process and add ‘value’ to the clinician. Value comes in various forms, whether it be a process that is seamlessly integrated into the hospital laboratory environment or one that can provide additional ‘information’ for the clinical pathologist in terms of risk profiling. We describe, herein, an efficient and tissue-conserving pipeline that uses Tissue Microarrays in a semi-automated process that could, one day, be integrated into the hospital laboratory domain, using seven putative prostate cancer biomarkers for illustration.

Read and download the paper for free here.

Aquila offer a range of routine through to advanced histological techniques for specialised projects, including tissue processing to wax, single and multiplex immunohistochemistry (IHC)/ immunofluorescence (IF), slide scanning and image analysis. Our team has the experience, expertise and specialist equipment to deliver technically demanding projects. Our ethos is to work closely with you to understand your histology requirements, and to tailor services specifically to meet your needs.

Get in touch to find out how Aquila’s Histology services can support your programs of work towards and in the clinic.

Contact